Abstract
Problem Maternal B vitamin deficiency increases the risk of fetal spina bifida (SB) and placental maldevelopment. It is unclear whether placental processes involving folate are altered in fetuses with SB in a contemporary cohort. We hypothesised that fetal SB would associate with reduced expression of key folate transporters (folate receptor-α [FRα], proton coupled folate receptor [PCFT], and reduced folate carrier [RFC]), and an increase in Hofbauer cell (HBC) abundance and folate receptor-β (FRβ) expression by HBCs.
Method of Study FRα, PCFT, and RFC protein localisation and expression (immunohistochemistry) and HBC phenotypes (RNA in situ hybridization) were assessed in placentae from fetuses with SB (cases; n=12) and with no congenital anomalies (controls; n=22).
Results Cases (vs. gestational age [GA]-matched controls) had a higher proportion of placental villous cells that were HBCs (6.9% vs. 2.4%, p=0.0001) and higher average FRβ expression by HBCs (3.2 mRNA molecules per HBC vs. 2.3, p=0.03). HBCs in cases were largely polarised to a regulatory phenotype (median 92.1% of HBCs). In sex-stratified analyses, male, but not female, cases had higher HBC levels and FRβ expression by HBCs than GA-matched controls. There were no differences between groups in the total percent of syncytium and stromal cells that were positive for FRα, PCFT, or RFC protein immunolabelling.
Conclusions HBC abundance and FRβ expression by HBCs are increased in placentae of fetuses with isolated SB, suggesting immune-mediated dysregulation in placental development and function, and could contribute to SB-associated comorbidities, such as poor fetal growth.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research is supported by the Canadian Institutes of Health Research (CIHR PJT-175161) and departmental research grants from the Department of Obstetrics and Gynaecology at Mount Sinai Hospital, Toronto, and the Department of Health Sciences at Carleton University, Ottawa. MW was supported by an Ontario Graduate Scholarship, Faculty of Science, Carleton University.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Research Ethics Boards of Carleton University (108884 and 106932) and Mount Sinai Hospital (17-0028-E and 17-0186-E) gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Minor edits to the manuscript text to clarify the cell phenotypes identified and study strengths and limitations have been made.
Data Availability
The data that support the findings of this study are available on reasonable request from the corresponding author, KLC.
